Fluoxetine alters mu opioid receptor expression in obese Zucker rat hypothalamus

Neuroscience Research Communications

Volumn 35, Issue 1, 2004, Pages 1-7

  Churruca, I ^a   Casis, L ^a   Portillo, M P ^a   Macarulla, M T ^a   Zarate J ^a   Pascual, J ^a   Echevarria E ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Fluoxetine; Food intake; Hypothalamus; Mu opioid receptor; Obese Zucker rat

Indexed keywords

FLUOXETINE; MU OPIATE RECEPTOR; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ARCUATE NUCLEUS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPOTHALAMUS; HYPOTHALAMUS NUCLEUS; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; IMMUNOHISTOCHEMISTRY; LATERAL HYPOTHALAMUS; MALE; MEDIAL PREOPTIC AREA; NERVE CELL; NONHUMAN; OBESITY; PROTEIN EXPRESSION; RAT; RAT STRAIN; SUPRACHIASMATIC NUCLEUS; SUPRAOPTIC NUCLEUS;

EID: 4644225107     PISSN: 08936609     EISSN: None     Source Type: Journal    
DOI: 10.1002/nrc.20014     Document Type: Article

References (24)

1. Beck B, Burlet A, Nicolas JP, Burlett C. Hypothalamic neuropeptide Y (NPY) in obese Zucker rats: implications in feeding and sexual behaviors. Physiol Behav 1990;47:449-453.
2. McKibbin PE, Cotton SJ, McMillan S, Holloway B, Mayers R, McCarthy HD, Williams G. Altered neuropeptide E concentrations in specific hypothalamic regions of obese (fa/fa) Zucker rats. Possible relationship to obesity and neuroendocrine disturbances. Diabetes 1991;40:1423-1429.
3. Beck B, Burlet A, Bazin R, Nicolas JP, Burlet C. Elevated neuropeptide Y in the arcuate nucleus of young obese Zucker rats may contribute to the development of their overeating. J Nutr 1993;123:1168-1172.
4. White BD, Martin RJ. Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. Proc Soc Exp Biol Med 1997;214:222-232.
5. Zarjevski N, Cusin I, Vettor R, Rhoner-Jeeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993;133:1756-1758.
6. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 2002;26:713-728.
7. Koch JE, Glass MJ, Cooper ML, Bodnar RJ. Alterations in deprivation, glucoprivic and sucrose intake following general, mu and kappa opioid antagonists in the hypothalamic paraventricular nucleus of rats. Neuroscience 1995;66(4):951-957.
8. Marin-Bivens CL, Olster DH. Opioid receptor blockade promotes weight loss and improves the display of sexual behaviors in obese Zucker female rats. Pharmacol Biochem Behav 1999;63(3):515-20.
9. Cole JL, Berman N, Bodnar RJ. Evaluation of chronic opioid receptor antagonist effects upon weight and intake measures in lean and obese Zucker rats. Peptides 1997;18(8):1201-7.
10. Weiss GF, Rogacki N, Fueg A, Buchen D, Suh JS, Wong DT, Leibowitz SF. Effect of hypothalamic and peripheral fluoxetine injection on natural pattern of macronutrient intake in the rat. Psychopharmacology 1991;105:467-476.
11. Anelli M, Bizzi A, Caccia S, Cadegoni AM, Fracasso C, Garattini S. Anorectic activity of fluoxetine and norfluoxetine in mice, rats and guinea pigs. Phar Pharmacol 1992;44:696-698.
12. Gandarias JM, Echevarría E, Acebes I, Abecia LC, Casis O, Casis L. Effects of fluoxetine administration on mu-opioid receptor immunostaining in the rat forebrain. Brain Res 1999;817:236-240.
13. Kim EM, O'Hare E, Grace MK, Welch CC, Billington CJ, Levine AS. ARC POMC mRNA and PVN alpha-MSH are lower in obese relative to lean zucker rats. Brain-Res 2000;862(1-2):11-6.
14. Jarosz PA, Metzger BL. The effect of opioid antagonism on food intake behavior and body weight in a biobehavioral model of obese binge eating. Biol Res Nurs 2002;3(4):198-209.
15. Roane DS, Iadarola MJ, Porter IR. Decreased [3H]-naloxone binding and elevated dynorphin-A(1-8) content in Zucker rat brain. Physiol-Behav 1988;43(3):371-4.
16. Cole JL, Berman N, Bodnar RJ. Evaluation of chronic opioid receptor antagonist effects upon weight and intake measures in lean and obese Zucker rats. Peptides 1997;18(8):1201-7.
17. Mitch CH, Leander JD, Mendelsohn LG, Shaw WN, Wong DT, Cantrell BE, Johnson BG, Reel JK, Snoddy JD, Takemori AE. 3,4-Dimethyl-4-(3-hydroxyphenyl) piperidines: opioid antagonists with potent anorectant activity. J Med Chem 1993;36(20):2842-50.
18. Gutiérrez A, Casado A, Rodríguez-Rivera VM, Macarulla MT, Echevarria E, Portillo MP. Efectos de la administración de fluoxetina en el peso corporal y el gasto energético en ratas obesas. Nutrición Básica 2001;21(3):9-13.
19. Giraudo SQ, Grace MK, Billington CJ, Levine AS. Differential effects of neuropeptide Y and the mu agonist DAMGO on "palatability" vs. "energy". Brain Res 1999;834:160-163.
20. Currie PJ, Coscina DV, Moretti J, Avellino MD. Paraventricular nucleus injections of naloxone methiodide inhibit NPY's effects on energy substrate utilization. Neuroreport 2000;11(4):733-5.
21. Giraudo SQ, Billimgton CJ, Levine AS. Effects of the opioid antagonist naltrexone on feeding induced by DAMGO in the central nucleus of the amygdala and in the paraventricular nucleus in the rat. Brain Res 1998;782(1-2)18-23.
22. Gutiérrez A, Saracíbar G, Casis L, Echevarría E, Rodríguez VM, Macarulla MT, Abecia LC, Portillo MP. Effects of fluoxetine administration on neuropeptide Y and orexins in obese Zucker rat hypothalamus. Obesity Res 2002;10:532-540.
23. Dryden S, Prankish HM, Wang Q, Williams G. Increased feeding and neuropeptide Y (NPY) but not NPY mRNA levels in the hypothalamus of the rat following central administration of the serotonin synthesis inhinitor p-chlorophenylalanine. Brain Res 1996;724:232-237.
24. Acebes A, Saracíbar G, Echevarría E, Casado A, Valiente FJ, Pascual J, Casis L. Selective serotonin reuptake inhibitors alter NPY immunostaining in the rat hypothalamus. Neurosci Res Commun 2002;30(3):185-196.